ORIGINAL ARTICLE
Distribution of CXCR4 and tumour-infiltrating lymphocytes in breast cancer subtypes; their relationship with each other, axillary lymph node involvement, and other prognostic indicators
Submission date: 2018-07-23
Final revision date: 2018-10-08
Acceptance date: 2018-10-17
Publication date: 2019-01-31
Pol J Pathol 2018;69(4):335-341
KEYWORDS
TOPICS
ABSTRACT
We have investigated the distribution of chemokine receptor 4 (CXCR4) and CD8-positive, tumour-infiltrating T lymphocytes (CD8+ TILs) in breast cancer subtypes and explored the relationship between them and the well-established conventional prognostic markers, including axillary lymph node involvement.
A total of 250 breast cancer patients were included in the study. The patients were separated into luminal A+B, HER2 enriched/overexpressed (HER2+), and triple-
negative, on the basis of their staining characteristics, via conventional staining methods. Immunohistochemical (IHC) staining for CXCR4 and CD8+ TILs were performed on the archival tissues from each patient.
With increasing intensity of CXCR4 staining, there was a higher incidence of lymph node metastasis (p < 0.01). Similarly, there was a positive correlation between the primary tumour size, HER2+ subtype, lymphovascular invasion, and axillary lymph node involvement. Dense lymphocytic infiltration was observed in HER2+ and triple-negative patients. No correlation between CD8+ TILs in all sites and breast cancer subtypes was discovered. A reverse correlation was discovered with CD8+ TILs stained only intratumorally and CXCR4 expression.
In conclusion, lymph node involvement correlates with higher CXCR4 expression in all breast cancer subtypes. Conversely, no such correlation is found with CD8+ TILs.
A total of 250 breast cancer patients were included in the study. The patients were separated into luminal A+B, HER2 enriched/overexpressed (HER2+), and triple-
negative, on the basis of their staining characteristics, via conventional staining methods. Immunohistochemical (IHC) staining for CXCR4 and CD8+ TILs were performed on the archival tissues from each patient.
With increasing intensity of CXCR4 staining, there was a higher incidence of lymph node metastasis (p < 0.01). Similarly, there was a positive correlation between the primary tumour size, HER2+ subtype, lymphovascular invasion, and axillary lymph node involvement. Dense lymphocytic infiltration was observed in HER2+ and triple-negative patients. No correlation between CD8+ TILs in all sites and breast cancer subtypes was discovered. A reverse correlation was discovered with CD8+ TILs stained only intratumorally and CXCR4 expression.
In conclusion, lymph node involvement correlates with higher CXCR4 expression in all breast cancer subtypes. Conversely, no such correlation is found with CD8+ TILs.
REFERENCES (36)
1.
Mahmoud MA, Paish EM, Powe DG, et al. Tumor-Infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol 2011; 29: 1949-1955.
2.
Denkert C, Loibl S, Noske A, et al. Tumor associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin. Oncol 2010; 28: 105-113.
3.
Denkert C, Minckwitz G, Brase JC, et al. Tumor-Infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2 – positive and triple negative primary breast cancer.
5.
Loi S, Sirtaine N, Piette F, et al. Prognostic and predictive value of tumor-Infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin- based chemotherapy: BIG 02-98. J Clin Oncol 2013; 31: 860-870.
6.
Adams S, Gray RJ, Demaria S, et al. Prognostic value of tumor-Infiltrating lymphocytes in triple negative breast cancer from two phase III randomized adjuvant breast cancer trial: ECOG 2197 and ECOG 1199. J Clin Oncol 2014; 32: 2959-2967.
7.
Ali HR, Glont SE, Blows FM, et al. PD-L1 protein Expression in Breast Cancer is rare, Enriched in Basal-like Tumours and Associated with Infiltrating lymphocytes. Ann Oncol 2015; 26: 1488-1493.
8.
Muller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001; 410: 50-56.
9.
Hwang JH, Hwang JH, Chung HK, et al. CXC chemokine receptor 4 expression and function in human anaplastic thyroid cancer cells. J Clin Endocrinol Metab 2003; 88: 408-416.
10.
Schrader AJ, Lechner O, Templin M, et al. CXCR4/CXCL12 expression and signaling in kidney cancer. Br J Cancer 2002; 86: 1250-1256.
11.
Voduc KD, Cheang MCU, Tyldesly S, et al. Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 2010: 28: 1684-1691.
12.
Salgado R, Denkert C, Demaria S, et al. The Evaluation of Tumor-Infiltrating Lymphocytes (TILs) in Breast Cancer: Recommendations by an International TILs Working Group 2014. Ann Oncol 2015; 26: 259-271.
13.
Bukholm IK, Nesland JM, Borresen D, et al. Re-expression of E-cadherin, alpha-catenin and beta-catenin, but not of gamma-.
16.
Yasuoka H, Tsujimoto M, Yoshidome K, et al. Cytoplasmic CXCR4 expression in breast cancer: induction by nitric oxide and correlation with lymph node metastasis and poor prognosis. BMC Cancer 2008; 8: 340.
17.
Adamkov M, Halasova E, Kajo K, et al. Survivin: a promising biomarker in breast carcinoma. Neoplasma 2010; 57: 572-577.
18.
Zhao Z, Lu P, Zhang H, et al. Nestin positively regulates the Wnt/β-catenin pathway and the proliferation, survival and invasiveness of breast cancer stem cells. Breast Cancer Res 2014; 16: 408-420.
19.
Liotta LA, Kohn EC. The microenvironment of the tumour-host-interface. Nature 2001; 411: 375-379.
20.
Vela M, Aris M, Llorente M, et al. Chemokine receptor-specific antibodies in cancer immunotherapy: achievements and challenges. Front Immunol 2015; 6: 12.
21.
Cabioglu N, Yazici MS, Arun B, et al. CCR7 and CXCR4 as novel biomarkers predicting axillary lymph node metastasis in T1 breast cancer. Clin Cancer Res 2005; 11: 5686-5693.
22.
Chu QD, Holm NT, Madumere P, et al. Chemokine receptor CXCR4 overexpression predicts recurrence for hormone receptor-positive, node-negative breast cancer patients. Surgery 2011; 149: 193-199.
23.
Sivrikoz ON, Doğanay L, Sivrikoz UK, et al. Distribution CXCR4 and gamma-catenin expression pattern in breast cancer subtypes and their relationship to axillary nodal involvement. Pol J Pathol 2013; 64: 253-259.
24.
Zhang Z, Ni C, Chen W, et al. Expression of CXCR4 and breast cancer prognosis: a systematic review and meta-analysis. BMC Cancer 2014; 14: 49.
25.
Liu Y, Li J, Gu X, et al. Correlation effect of EGFR and CXCR4 and CCR7 chemokine receptors in predicting breast cancer metastasis and prognosis. J Exp Clin Cancer Res 2010; 29: 16-25.
26.
Mueller A, Homey B, Soto H, et al. Involvement of the chemokine receptors in breast cancer metastasis. Nature 2001; 410: 50-56.
27.
Ali HR, Provenzano E, Dawson SJ, et al. Association between CD8+ T-cell infiltration and breast cancer survival in 12439 patients. Ann Oncol 2014; 25: 1536-1543.
30.
negative breast cancer: a meta-analysis Breast Cancer Res Treat 2014; 148: 467-476.
31.
Macchetti AH, Marana HRC, Silva JS, et al. Tumor-infiltrating CD4+ T lymphocytes in early breast cancer reflect lymph node involvement. Clinics 2006; 61: 203-208.
32.
Matkowski R, Gisterek I, Halon A. The Prognostic Role of Tumor-infiltrating CD4 and CD8 T Lymphocytes in Breast Cancer. Anticancer Res 2009; 29: 2445-2452.
33.
Khedr RAG, Ghannam AA, Rashidy MA, et al. The prognostic role of tumor-infiltrating lymphocytes CD8 and Foxp3 and their impact on recurrence in breast cancer patients. J Cancer Sci Ther 2016; 8: 7.
34.
Zhang S, Zhang D, Gong M, et al. High lymphatic vessel density and presence of lymphovascular invasion both predict poor prognosis in breast cancer. BMC Cancer 2017; 17: 335.
35.
Howland K, Driver T, Sedrak M. Lymph node involvement in immunohistochemistry-based molecular classifications of breast cancer. J Surg Res 2013; 185: 697-703.
36.
Seok Park H, Heo I, Ye Kim J, et al. No effect of tumor-infiltrating lymphocytes (TILs) on prognosis in patients with early triple-negative breast cancer: Validation of recommendations by the International TILs Working Group 2014. J Surg Oncol 2016; 114: 17-21.
Share
RELATED ARTICLE
| eISSN: | 2084-9869 |
| ISSN: | 1233-9687 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
